Program
Prednisolone
Also written as “Desloratadine + Prednisolone”, “prednisolone” and “Desloratadine , Prednisolone”.
Its studies are mostly in Prostatic Neoplasms · Arthritis, Rheumatoid · Rhinitis, Allergic · Asthma · Pulmonary Disease, Chronic Obstructive, led by 13 companies.
Drug pagePrednisolone: every studyMany companies study it; this page follows only the 26 they lead. All 247 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 50 open or running | phase 3since Mar 11, 2010 | Aug 24, 2005 | none ahead |
| Sanofiits history only | 50 open or running | phase 4since Feb 26, 2014 | Jul 9, 2007 | none ahead |
| EMSits history only | 40 open or running | phase 3since Sep 5, 2011 | Sep 5, 2011 | none ahead |
| Astellas Pharmaits history only | 32 open or running | phase 2since May 27, 2025 | Jun 26, 2024 | Oct 31, 2027phase 2 · NCT07052929 |
| Adapt Produtos Oftalmológicos Ltda.its history only | 10 open or running | phase 3since Mar 22, 2011 | Mar 22, 2011 | none ahead |
| Bausch Health Companiesits history only | 10 open or running | phase 3since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Biogenits history only | 10 open or running | phase 4since Jul 29, 2010 | Jul 29, 2010 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 4since Jan 3, 2019 | Jan 3, 2019 | none ahead |
| Eurofarma Laboratoriosits history only | 10 open or running | phase 3since Dec 13, 2021 | Dec 13, 2021 | none ahead |
| Hamad Medicalits history only | 10 open or running | phase 3since Nov 7, 2012 | Nov 7, 2012 | none ahead |
| Hoffmann-La Rocheits history only | 10 open or running | phase 2since Sep 6, 2013 | Sep 6, 2013 | none ahead |
| Ultragenyx Pharmaceuticalits history only | 10 open or running | phase 3since Jul 14, 2021 | Jul 14, 2021 | none ahead |
| Zalicusits history only | 10 open or running | phase 2since Jun 7, 2011 | Jun 7, 2011 | none ahead |
Also a collaborator on its studies: Elan Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Aug 24, 2005.
- Sep 5, 2011EMS’ first study: phase 3 study in EczemaNew to EMSEMS · NCT01429701 · 76 enrolled
- Feb 6, 20122 phase 3 studiesEMS · NCT01529242, NCT01529229
- Oct 31, 2012Phase 3 study in Rhinitis, AllergicEMS · NCT01720485 · 234 enrolled · Brazil
- Nov 7, 2012Hamad Medical’s first study: phase 3 study in Arthritis, RheumatoidNew to Hamad MedicalHamad Medical · NCT01724268 · 80 enrolled · Qatar
- Sep 6, 2013Hoffmann-La Roche’s first study: phase 2 study in AsthmaNew to Hoffmann-La RocheHoffmann-La Roche · NCT01948401 · 54 enrolled · United Kingdom
- Feb 26, 2014Phase 4 study in Prostate Cancer MetastaticSanofi · NCT02074137 · 10 enrolled · India
- May 8, 2015Phase 4 study in Prostatic NeoplasmsSanofi · NCT02441894 · 21 enrolled · Japan
- Nov 2, 2017Phase 3 study in Multiple SclerosisSanofi · NCT03368664 · 16 enrolled · France, Italy, Poland and more
- Jan 3, 2019Chong Kun Dang Pharmaceutical’s first study: phase 4 study in Kidney TransplantNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT03794492 · 169 enrolled · Korea, Republic of
- Jul 14, 2021Ultragenyx Pharmaceutical’s first study: phase 3 study in Hepatorenal form of glycogen storage diseaseNew to Ultragenyx PharmaceuticalUltragenyx Pharmaceutical · NCT05139316 · 52 enrolled · United States, Brazil, Canada and more
- Dec 13, 2021Eurofarma Laboratorios’ first study: phase 3 study in Rhinitis, AllergicNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT05214911 · 262 enrolled · Brazil
- Jun 26, 2024Astellas Pharma’s first study: phase 1 study in Friedreich AtaxiaNew to Astellas PharmaAstellas Pharma · NCT06483802
- May 27, 2025Phase 2 study in Prostatic NeoplasmsAstellas Pharma · NCT07005154 · 218 planned · United States, China, France and more
- Jun 30, 2025Phase 2 study in Myopathies, Structural, CongenitalAstellas Pharma · NCT07052929 · 9 planned · United States, Canada
Ahead
- Oct 31, 2027Primary completion: phase 2 study in Myopathies, Structural, CongenitalAstellas Pharma · NCT07052929
- May 31, 2032Primary completion: phase 2 study in Prostatic NeoplasmsAstellas Pharma · NCT07005154
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07052929Myopathies, Structural, Congenital · United States, Canada | 2 | Recruiting | Astellas Pharma | Oct 31, 2027 | 9 |
| NCT07005154Prostatic Neoplasms · United States, China, France and more | 2 | Recruiting | Astellas Pharma | May 31, 2032 | 218 |
| NCT06483802Friedreich Ataxia | 1 | Withdrawn | Astellas Pharma | Oct 22, 2025 | 0 |
| NCT05214911Rhinitis, Allergic · Brazil | 3 | Completed | Eurofarma Laboratorios | Mar 23, 2025 | 262 |
| NCT05139316Hepatorenal form of glycogen storage disease · United States, Brazil, Canada and more | 3 | Completed | Ultragenyx Pharmaceutical | Feb 20, 2024 | 52 |
| NCT03794492Kidney Transplant · Korea, Republic of | 4 | Completed | Chong Kun Dang Pharmaceutical | Jul 22, 2022 | 169 |
| NCT03368664Multiple Sclerosis · France, Italy, Poland and more | 3 | Terminated | Sanofi | May 4, 2021 | 16 |
| NCT02441894Prostatic Neoplasms · Japan | 4 | Completed | Sanofi | Feb 2016 | 21 |
| NCT02074137Prostate Cancer Metastatic · India | 4 | Completed | Sanofi | Mar 2016 | 10 |
| NCT01948401Asthma · United Kingdom | 2 | Completed | Hoffmann-La Roche | Apr 2014 | 54 |
| NCT01724268Arthritis, Rheumatoid · Qatar | 3 | UNKNOWN | Hamad Medical | May 2014 | 80 |
| NCT01720485Rhinitis, Allergic · Brazil | 3 | UNKNOWN | EMS | Dec 2013 | 234 |
| NCT01529242Cutaneous Hypersensitivity · Brazil | 3 | Terminated | EMS | Aug 2016 | 17 |
| NCT01529229Rhinitis, Allergic | 3 | Completed | EMS | Oct 2014 | 210 |
| NCT01429701Eczema | 3 | Completed | EMS | Jun 2012 | 76 |
| NCT01369745Arthritis, Rheumatoid · United States | 2 | Completed | Zalicus | Aug 2012 | 294 |
| NCT01603030Eye Infections · Brazil | 3 | UNKNOWN | Adapt Produtos Oftalmológicos Ltda. | Aug 2012 | 66 |
| NCT01324583Prostatic Neoplasms · Japan | 1 | Completed | Sanofi | Nov 2014 | 48 |
| NCT01211665Immune Reconstitution Inflammatory Syndrome · United States, Germany | 4 | Terminated | Biogen | Feb 2012 | 3 |
| NCT01086410Asthma · United States, Germany, Poland | 3 | Completed | GlaxoSmithKline | Sep 2010 | 185 |
| NCT00498797Prostatic Neoplasms · Brazil, Germany, Hungary and more | 2 | Completed | Sanofi | Jul 2007 | 86 |
| NCT00384306Pulmonary Disease, Chronic Obstructive · United Kingdom | 1 | Completed | GlaxoSmithKline | Jan 2006 | 9 |
| NCT00379730Pulmonary Disease, Chronic Obstructive · Argentina, Chile, New Zealand and more | 1 | Completed | GlaxoSmithKline | 90 | |
| NCT00327197Asthma · United Kingdom | 1 | Terminated | GlaxoSmithKline | Jun 6, 2011 | 47 |
| NCT00198523Eye Infections · United States | 3 | Completed | Bausch Health Companies | Oct 2005 | 132 |
| NCT00134693Arthritis, Rheumatoid · Australia, France, Germany and more | 2 | Completed | GlaxoSmithKline | Aug 3, 2006 | 77 |
How it is read
Names in the registry
- “Prednisolone”, 17 entries
- “Desloratadine + Prednisolone”, 3 entries
- “prednisolone”, 3 entries
- “Desloratadine , Prednisolone”, 1 entry
- “Oral prednisolone”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 7 studies
- Arthritis, Rheumatoid, 4 studies
- Rhinitis, Allergic, 3 studies
- Asthma, 3 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.